Skip to Content

OVERVIEW

Karen Mangasarian counsels biotechnology, pharmaceutical, and other life sciences clients on all aspects of intellectual property. She has extensive experience in the management of worldwide patent portfolios, patent life cycle management, and the development of competitive patent strategies. She assists clients with competitive patent landscapes, patent invalidity, patentability, non-infringement, and freedom-to-operate analyses.

Karen performs IP due diligence investigations and advises on IP issues in the context of transactions, including license agreements, joint ventures, collaboration agreements, and mergers and acquisitions.

Karen has successfully worked with clients across a wide range of technology areas in life sciences including small molecule pharmaceuticals, pharmaceutical formulations, antibodies, protein therapeutics, gene therapy, CRISPR and diagnostic and therapeutic methods in molecular and cellular biology, immunology, microbiology, biochemistry, genomics, and computational biology.

Karen also has extensive experience in contentious patent matters, including interferences, re­examinations, oppositions, and litigation.

 Representative Matters:

  • Represented an academic institution in an interference relating to diagnostic methods for detecting cancer-associated mutations.
  • Represented a biotechnology company in an interference relating to beta interferon.
  • Represented a biopharmaceutical company in an interference relating to a G protein-coupled receptor.
  • Represented a biotechnology company in an interference relating to tumor necrosis factor ligand.
  • Represented a biotechnology company in an interference relating to an osteogenic protein.
  • Represented a biotechnology company in an interference relating to transgenic fibrinogen.
  • Represented a biopharmaceutical company in challenging a patent relating to a method for screening for specific GPCRs.
  • Represented a biotechnology company in defending its patent relating to heterologous expression of polypeptides in filamentous fungi.
  • Represented an academic hospital in an unjust enrichment and unfair trade practices case involving patents directed to a method for treating age-related macular degeneration.
  • Represented an academic hospital in a patent infringement litigation involving patents directed to a method for treating age-related macular degeneration.

Honors & Awards

    • IAM Patent 1000 (2014-2019, 2022-2024)
    • Managing IP Patent Star (2021, 2023, 2024)
    • Best Lawyers (2023)
    • NY Super Lawyers (2021-2024)
    • WIPR Leaders (2024)

Memberships & Affiliations

    • New York Intellectual Property Association
    • Intellectual Property Owners Association (IPO)
      • Pharmaceutical & Biotechnology Issues Committee